24/7 Market News Snapshot 05 March, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

March 5, 2025

DENVER, Colo., 05 March, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (NASDAQ:SLXN) is experiencing a significant surge in interest as shares have reached $1.379, reflecting a remarkable 24.23% increase from the previous close of $1.110 during pre-market trading. This impressive gain is underpinned by a trading volume of 4.57 million shares, indicative of strong investor confidence in the company’s potential. Analysts are keenly observing SLXN as it stands poised to capture growing attention within the biotechnology sector.

In conjunction with this market momentum, Silexion has recently unveiled promising preclinical data regarding its innovative RNA interference therapy, SIL204, designed to combat KRAS-driven pancreatic cancers. The latest studies demonstrate that SIL204 substantially curtails primary tumor growth and minimizes metastatic spread when delivered subcutaneously in orthotopic pancreatic cancer models. These results represent a significant advancement in addressing both primary and metastatic manifestations of this aggressive disease.

SIL204 has shown formidable efficacy across diverse pancreatic cancer cell lines characterized by different KRAS mutations. For instance, in the AsPC-1 model with the KRAS G12D mutation, treatment resulted in a nearly 70% reduction in tumor bioluminescence by day 28 when compared to control groups. Similar efficacy was noted in Panc-1 and BxPC-3 models, reinforcing SIL204’s potential as a transformative treatment option for those affected by pancreatic cancer.

Dr. Mitchell Shirvan, Silexion’s Chief Scientific Officer, emphasized the significance of these findings, stating that they represent a pivotal advancement in developing new cancer therapies. As the company hones its development strategy, it remains dedicated to innovating therapeutic options for patients facing daunting cancer challenges, solidifying its role in the evolving biotechnology landscape. With robust clinical data and increasing stock performance, Silexion is positioning itself as a notable player in the treatment of KRAS-driven cancers.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.